Absence of E2f1 Negates Pro-osteogenic Impacts of p21 Absence
- PMID: 38643416
- DOI: 10.1007/s00223-024-01210-7
Absence of E2f1 Negates Pro-osteogenic Impacts of p21 Absence
Abstract
Loss of p21 leads to increased bone formation post-injury; however, the mechanism(s) by which this occurs remains undetermined. E2f1 is downstream of p21 and as a transcription factor can act directly on gene expression; yet it is unknown if E2f1 plays a role in the osteogenic effects observed when p21 is differentially regulated. In this study we aimed to investigate the interplay between p21 and E2f1 and determine if the pro-regenerative osteogenic effects observed with the loss of p21 are E2f1 dependent. To accomplish this, we employed knockout p21 and E2f1 mice and additionally generated a p21/E2f1 double knockout. These mice underwent burr-hole injuries to their proximal tibiae and healing was assessed over 7 days via microCT imaging. We found that p21 and E2f1 play distinct roles in bone regeneration where the loss of p21 increased trabecular bone formation and loss of E2f1 increased cortical bone formation, yet loss of E2f1 led to poorer bone repair overall. Furthermore, when E2f1 was absent, either individually or simultaneously with p21, there was a dramatic decrease of the number of osteoblasts, osteoclasts, and chondrocytes at the site of injury compared to p21-/- and C57BL/6 mice. Together, these results suggest that E2f1 regulates the cell populations required for bone repair and has a distinct role in bone formation/repair compared to p21-/-E2f1-/-. These results highlight the possibility of cell cycle and/or p21/E2f1 being potential druggable targets that could be leveraged in clinical therapies to improve bone healing in pathologies such as osteoporosis.
Keywords: Bone healing; Cell cycle regulation; E2f1; Osteogenesis; p21.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Thompson Z, Miclau T, Hu D, Helms JA (2002) A model for intramembranous ossification during fracture healing. J Orthop Res 20(5):1091–1098. https://doi.org/10.1016/S0736-0266(02)00017-7 - DOI - PubMed
-
- Mistry AS, Mikos AG (2005) Tissue engineering strategies for bone regeneration. Adv Biochem Eng Biotechnol 94:1–22. https://doi.org/10.1007/B99997 - DOI - PubMed
-
- Watson-Levings RS, Palmer GD, Levings PP, Dacanay EA, Evans CH, Ghivizzani SC (2022) Gene therapy in orthopaedics: progress and challenges in pre-clinical development and translation. Front Bioeng Biotechnol. https://doi.org/10.3389/FBIOE.2022.901317 - DOI - PubMed - PMC
-
- Baroli B (2009) From natural bone grafts to tissue engineering therapeutics: brainstorming on pharmaceutical formulative requirements and challenges. J Pharm Sci 98(4):1317–1375. https://doi.org/10.1002/JPS.21528 - DOI - PubMed
-
- Amini AR, Laurencin CT, Nukavarapu SP (2012) Bone tissue engineering: recent advances and challenges. Crit Rev Biomed Eng 40(5):363. https://doi.org/10.1615/CRITREVBIOMEDENG.V40.I5.10 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
